Patterns of erythropoiesis-stimulating agent use for chemotherapy-induced anemia in lung cancer: results of a retrospective Hungarian real-life clinical data analysis
| Autor: | György Losonczy, Noémi Eszes, Lilla Tamási, Marianna Budai, Tamás Kardos, Mária Szilasi, Veronika Müller, Krisztina Vincze |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
Research design medicine.medical_specialty Lung Neoplasms Anemia medicine.drug_class medicine.medical_treatment Statistics as Topic Antineoplastic Agents Chemotherapy induced anemia hemic and lymphatic diseases Internal medicine Humans Medicine Pharmacology (medical) Lung cancer Retrospective Studies Hungary Chemotherapy business.industry General Medicine Middle Aged medicine.disease Erythropoiesis-stimulating agent Small Cell Lung Carcinoma Surgery Erythropoietin Hematinics Female Hemoglobin business medicine.drug |
| Zdroj: | Expert Opinion on Drug Safety. 10:503-507 |
| ISSN: | 1744-764X 1474-0338 |
| DOI: | 10.1517/14740338.2011.571200 |
| Popis: | Lung cancer carries a relatively high risk of chemotherapy-induced anemia, one of the most frequent hematological complications. Previous data show a lack of optimal anemia correction in patients with chemotherapy-induced anemia. This paper analyzes real-life data considering the prevalence and severity of chemotherapy-induced anemia, together with the frequency and efficacy of erythropoietin treatment of anemia in Hungarian lung cancer patients.Data of 482 patients with histological or cytological confirmed lung cancer receiving chemotherapy were collected retrospectively between 1 January and 31 December, 2008. In all, 83 (17%) of them developed chemotherapy-induced moderate to severe anemia (44.6% male, 55.4% female; mean age 70 ± 8.6 years; NSCLC 67.5%, small cell lung cancer 32.5%).More than 50% of the patients suffering from moderate to severe chemotherapy-induced anemia (hemoglobin below 10 g/dl) did not receive erythropoietin treatment. Chemotherapy had to be postponed due to anemia in 32.26% of the patients receiving erythropoietin supplementation, while this was seen in 41.94% of the group without erythropoietin treatment (p0.05). In patients not receiving erythropoietin, the severity of anemia increased, while erythropoietin treated patients maintained acceptable hemoglobin levels after the end of the chemotherapy.The data draws attention to the fact that nowadays chemotherapy-induced anemia is not treated according to current guidelines in many lung cancer cases in Hungary. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|